SCHEMBL3933099

SCHEMBL3933099

CCOC(=O)c1ccc2c(c1)NC(=O)C2=C(Nc1ccc(CN(C)C)cc1)c1ccc2c(c1)OCO2

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.52
RAB9A P51151 7/20 0.52
TSHR P16473 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
ALDH1A1 P00352 4/20 0.48
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
LMNA P02545 3/20 0.48
USP2 O75604 2/20 0.48
ALOX15 P16050 1/20 0.48
HSD17B10 Q99714 1/20 0.48
NPC1 O15118 6/20 0.47
NPSR1 Q6W5P4 1/20 0.46
MAPK1 P28482 3/20 0.43
SMN1; SMN2 Q16637 3/20 0.41
CASP3 P42574 1/20 0.41
SENP7 Q9BQF6 1/20 0.41
KDM4E B2RXH2 2/20 0.41
PKM P14618 1/20 0.41
RXFP1 Q9HBX9 3/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3933096 1.00 MAPT (0.52) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3936934 0.95 MAPT (0.49) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3936941 0.95 MAPT (0.49) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3942797 0.94 RAB9A (0.48) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3942795 0.94 RAB9A (0.48) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3943159 0.93 MAPT (0.51) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3943156 0.93 MAPT (0.51) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3934167 0.89 MAPT (0.52) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3934164 0.89 MAPT (0.52) MAPTRAB9ATSHRL3MBTL1ALDH1A1
SCHEMBL3933791 0.89 MEN1 (0.43) MAPTRAB9ATSHRALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1551830-B1 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA (DE) 2009-04-08 EP disclosed
US-7148249-B2 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-12-12 US disclosed
EP-1551830-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBATORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-07-13 EP disclosed
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-03-10 US disclosed
WO-2004026829-A2 HETEROCYCLICALLY SUBSTITUTED INDOLINONES AND THEIR USE AS RECEPTOR TYROSINE KINASE INHIBITORS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054710-A1 Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments CDK1, CDK2, CDK3 MAPT 1798/4885RAB9A 3709/4885TSHR 966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.